MiR-34a-3p suppresses pulmonary vascular proliferation in acute pulmonary embolism rat by targeting DUSP1

Yang Li1, Jinyan Shao1, Jianfeng Song1

  • 1Department of Emergency, Minhang Hospital, Fudan University, Shanghai, China.

Bioscience Reports
|November 15, 2021
PubMed
Abstract

Insights

This study reveals that miR-34a-3p is downregulated in acute pulmonary embolism (APE). Upregulating miR-34a-3p may treat APE by inhibiting pulmonary vascular proliferation.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Pulmonary Medicine

Background:

  • Acute pulmonary embolism (APE) significantly contributes to cardiovascular morbidity and mortality.
  • MicroRNAs (miRNAs) play crucial roles in various disease processes.
  • Identifying key miRNAs in APE is essential for understanding its pathogenesis.

Purpose of the Study:

  • To identify differentially expressed miRNAs in APE.
  • To investigate the functional role of a critical miRNA in APE.
  • To explore the therapeutic potential of targeting this miRNA.

Main Methods:

  • Bioinformatics analysis to screen for critical miRNAs and target genes.
  • In vitro assays (dual-luciferase, RNA pull-down) to confirm binding.
  • Establishment of a rat model of APE and PDGF-BB-induced human pulmonary artery smooth muscle cells (PASMCs).
  • Assessment of pulmonary arterial pressure, histological changes, and cell proliferation.
  • Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot to determine gene and miRNA expression.

Main Results:

  • MiR-34a-3p expression was found to be downregulated in APE patients and rats.
  • Upregulation of miR-34a-3p attenuated pulmonary hypertension and arterial wall thickening in APE rats.
  • MiR-34a-3p directly suppressed DUSP1 expression, inhibiting PASMC proliferation.
  • Downregulation of miR-34a-3p was associated with increased NOR-1 and PCNA levels.

Conclusions:

  • Upregulated miR-34a-3p negatively regulates DUSP1 expression.
  • Inhibition of PASMC proliferation by miR-34a-3p may offer a therapeutic strategy for APE.
  • Targeting miR-34a-3p could be a novel approach for treating APE by modulating pulmonary vascular proliferation.